105 related articles for article (PubMed ID: 10408800)
1. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer.
Ward RL; Hawkins NJ; Coomber D; Disis ML
Hum Immunol; 1999 Jun; 60(6):510-5. PubMed ID: 10408800
[TBL] [Abstract][Full Text] [Related]
2. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
Disis ML; Pupa SM; Gralow JR; Dittadi R; Menard S; Cheever MA
J Clin Oncol; 1997 Nov; 15(11):3363-7. PubMed ID: 9363867
[TBL] [Abstract][Full Text] [Related]
3. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.
Disis ML; Knutson KL; Schiffman K; Rinn K; McNeel DG
Breast Cancer Res Treat; 2000 Aug; 62(3):245-52. PubMed ID: 11072789
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
5. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis ML; Calenoff E; McLaughlin G; Murphy AE; Chen W; Groner B; Jeschke M; Lydon N; McGlynn E; Livingston RB
Cancer Res; 1994 Jan; 54(1):16-20. PubMed ID: 7505195
[TBL] [Abstract][Full Text] [Related]
6. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
Goodell V; Waisman J; Salazar LG; de la Rosa C; Link J; Coveler AL; Childs JS; Fintak PA; Higgins DM; Disis ML
Mol Cancer Ther; 2008 Mar; 7(3):449-54. PubMed ID: 18319334
[TBL] [Abstract][Full Text] [Related]
7. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.
Park DI; Kang MS; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Han WK; Kim H; Ryu SH; Sepulveda AR
Int J Colorectal Dis; 2007 May; 22(5):491-7. PubMed ID: 16947041
[TBL] [Abstract][Full Text] [Related]
9. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against the HER-2/neu oncogenic protein.
Bernhard H; Salazar L; Schiffman K; Smorlesi A; Schmidt B; Knutson KL; Disis ML
Endocr Relat Cancer; 2002 Mar; 9(1):33-44. PubMed ID: 11914181
[TBL] [Abstract][Full Text] [Related]
12. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
13. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
14. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.
Disis ML; Goodell V; Schiffman K; Knutson KL
J Clin Immunol; 2004 Sep; 24(5):571-8. PubMed ID: 15359116
[TBL] [Abstract][Full Text] [Related]
15. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
16. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.
Disis ML; Cheever MA
Adv Cancer Res; 1997; 71():343-71. PubMed ID: 9111870
[TBL] [Abstract][Full Text] [Related]
18. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
19. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Taylor C; Hershman D; Shah N; Suciu-Foca N; Petrylak DP; Taub R; Vahdat L; Cheng B; Pegram M; Knutson KL; Clynes R
Clin Cancer Res; 2007 Sep; 13(17):5133-43. PubMed ID: 17785568
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
